Comparison 12. Valproate vs topiramate.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Individual adverse events (children and adolescents)	1		Odds Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 Blurred vision	1	142	Odds Ratio (M‐H, Random, 95% CI)	0.19 [0.01, 4.12]
1.2 Dizziness	1	142	Odds Ratio (M‐H, Random, 95% CI)	1.0 [0.51, 1.98]
1.3 Drowsiness	1	142	Odds Ratio (M‐H, Random, 95% CI)	0.34 [0.15, 0.79]
1.4 Hair loss	1	142	Odds Ratio (M‐H, Random, 95% CI)	1.0 [0.14, 7.30]
1.5 Headache	1	142	Odds Ratio (M‐H, Random, 95% CI)	0.65 [0.17, 2.40]
1.6 Muscle weakness	1	142	Odds Ratio (M‐H, Random, 95% CI)	2.29 [0.91, 5.76]
1.7 Nausea	1	142	Odds Ratio (M‐H, Random, 95% CI)	0.40 [0.17, 0.95]
1.8 Paresthesia	1	142	Odds Ratio (M‐H, Random, 95% CI)	1.43 [0.68, 2.99]
1.9 Speech‐related problems	1	142	Odds Ratio (M‐H, Random, 95% CI)	1.0 [0.24, 4.16]
1.10 Tremor	1	142	Odds Ratio (M‐H, Random, 95% CI)	1.60 [0.73, 3.48]
2 Change in symptom severity (children and adolescents)	2		Std. Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 at 5‐12 weeks	2	149	Std. Mean Difference (IV, Random, 95% CI)	‐0.41 [‐1.16, 0.35]
3 Dropout rates (children and adolescents)	1		Odds Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Adverse events	1	30	Odds Ratio (M‐H, Random, 95% CI)	0.31 [0.01, 8.28]
3.2 All cause	1	30	Odds Ratio (M‐H, Random, 95% CI)	0.31 [0.01, 8.28]